Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
27.12
-0.79 (-2.83%)
At close: Mar 6, 2026, 4:00 PM EST
26.84
-0.28 (-1.03%)
After-hours: Mar 6, 2026, 7:55 PM EST
Castle Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 344.23 | 332.07 | 219.79 | 137.04 | 94.09 | Upgrade
|
| Revenue Growth (YoY) | 3.66% | 51.09% | 60.38% | 45.65% | 50.18% | Upgrade
|
| Cost of Revenue | 71.03 | 60.21 | 44.98 | 32.01 | 15.82 | Upgrade
|
| Gross Profit | 273.2 | 271.86 | 174.81 | 105.03 | 78.26 | Upgrade
|
| Selling, General & Admin | 229.32 | 200.05 | 180.15 | 143 | 86.74 | Upgrade
|
| Research & Development | 51.85 | 52.04 | 53.62 | 44.9 | 29.65 | Upgrade
|
| Amortization of Goodwill & Intangibles | 14.74 | 11.11 | 9.01 | 8.27 | 1.96 | Upgrade
|
| Operating Expenses | 295.91 | 263.19 | 242.78 | 196.17 | 118.34 | Upgrade
|
| Operating Income | -22.71 | 8.67 | -67.98 | -91.14 | -40.08 | Upgrade
|
| Interest Expense | -0.09 | -0.58 | -0.01 | -0.02 | -0 | Upgrade
|
| Interest & Investment Income | 11.77 | 12.92 | 10.62 | 3.97 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.14 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -10.88 | 21.01 | -57.37 | -87.19 | -40.01 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.47 | 0.56 | - | - | - | Upgrade
|
| Asset Writedown | -20.1 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 18.29 | - | Upgrade
|
| Pretax Income | -29.51 | 21.56 | -57.37 | -68.9 | -40.01 | Upgrade
|
| Income Tax Expense | -5.36 | 3.32 | 0.1 | -1.77 | -8.72 | Upgrade
|
| Net Income | -24.16 | 18.25 | -57.47 | -67.14 | -31.29 | Upgrade
|
| Net Income to Common | -24.16 | 18.25 | -57.47 | -67.14 | -31.29 | Upgrade
|
| Shares Outstanding (Basic) | 29 | 28 | 27 | 26 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 29 | 27 | 26 | 25 | Upgrade
|
| Shares Change (YoY) | -0.92% | 9.15% | 2.87% | 3.65% | 32.80% | Upgrade
|
| EPS (Basic) | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 | Upgrade
|
| EPS (Diluted) | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 | Upgrade
|
| Free Cash Flow | 28.33 | 36.54 | -19.25 | -47.29 | -22.47 | Upgrade
|
| Free Cash Flow Per Share | 0.98 | 1.25 | -0.72 | -1.81 | -0.89 | Upgrade
|
| Gross Margin | 79.37% | 81.87% | 79.53% | 76.64% | 83.18% | Upgrade
|
| Operating Margin | -6.60% | 2.61% | -30.93% | -66.51% | -42.60% | Upgrade
|
| Profit Margin | -7.02% | 5.49% | -26.15% | -48.99% | -33.26% | Upgrade
|
| Free Cash Flow Margin | 8.23% | 11.00% | -8.76% | -34.51% | -23.88% | Upgrade
|
| EBITDA | -2.04 | 24.67 | -55.65 | -80.6 | -36.67 | Upgrade
|
| EBITDA Margin | -0.59% | 7.43% | -25.32% | -58.81% | -38.98% | Upgrade
|
| D&A For EBITDA | 20.67 | 16 | 12.33 | 10.54 | 3.41 | Upgrade
|
| EBIT | -22.71 | 8.67 | -67.98 | -91.14 | -40.08 | Upgrade
|
| EBIT Margin | -6.60% | 2.61% | -30.93% | -66.51% | -42.60% | Upgrade
|
| Effective Tax Rate | - | 15.39% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.